15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Janux Therapeutics Inc, 10 rate it Buy or better, 2 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets range widely, $23.00 to $55.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $35.17 sits 82% above the current $19.32. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.57 next quarter toward $-2.62 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Moderate Buy
Strong Buy00%
Buy1077%
Hold215%
Sell18%
Strong Sell00%
Based on 13 analysts giving stock ratings to Janux Therapeutics Inc.
As of Sep, 10 of 13 firms rate JANX a Buy (2 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
JANX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.57
Range $-0.81 – $-0.32 · 14 analysts · +11% YoY
Next period, 14 analysts expect Janux Therapeutics Inc to earn $-0.57 a share (range $-0.81 – $-0.32), versus $-0.51 a year earlier. Full-year consensus is $-1.73, growing to $-2.62 the year after.
REVENUE · NEXT QUARTER
$7.3M
Range $0 – $43.8M · 14 analysts
Revenue is expected to reach $7.3M (range $0 – $43.8M). Full-year consensus is $29.5M, rising to $8.1M next year.
Top analysts covering Janux Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on JANX.
#1
George Farmer
Scotiabank · Rank #240
Hold
$36.00+86.3% to target
Overall win rate
44%
+ Follow
#2
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #252
Buy
$45.00+132.9% to target
Overall win rate
38%
+ Follow
#3
SW
Stephen Willey
Stifel · Rank #345
Buy
$38.00+96.7% to target
Overall win rate
31%
+ Follow
#4
Robert Driscoll
Wedbush · Rank #375
Buy
$36.00+86.3% to target
Overall win rate
30%
+ Follow
#5
Kelsey Goodwin
Piper Sandler
Buy
$26.00+34.6% to target
Coverage
—
+ Follow
JANX stock forecast FAQ
What is JANX's average 12-month price target?+
The 6 analysts with a live target average $35.17 for Janux Therapeutics Inc over the next 12 months, ranging from a $55.00 high to a $23.00 low.
Is JANX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 13 analyst ratings, 10 are Buy or Strong Buy, 2 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for JANX?+
The Street-high target is $55.00 (Guggenheim), and the Street-low is $23.00 (Wolfe Research). The average of all 6 active targets is $35.17.
How many Wall Street analysts cover JANX?+
13 analysts have an active rating on Janux Therapeutics Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering JANX?+
Among analysts who currently cover JANX, George Farmer of Scotiabank has the strongest overall Quantellect track record (Rank #240). Their current call is Hold with a $36.00 target.
What is Janux Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.57 per share (range $-0.81 – $-0.32) across 14 analysts. Full-year EPS is projected at $-1.73, rising to $-2.62 the following year.
How much revenue is Janux Therapeutics Inc expected to report next quarter?+
Consensus revenue is $7.3M (range $0 – $43.8M). Full-year revenue is projected at $29.5M, growing to $8.1M next year.
Have analysts been upgrading or downgrading JANX lately?+
As of Sep, 10 of 13 firms rate JANX a Buy (2 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their JANX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
